 | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Eliminationhalf-life | 3-4 hours[1] |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H14ClFN2O3 |
| Molar mass | 348.76 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) | |
Doxefazepam (marketed under brand nameDoxans) is abenzodiazepine medication. It possessesanxiolytic,anticonvulsant,sedative andskeletal muscle relaxant properties. It is used therapeutically as ahypnotic.[2] According to Babbini and colleagues in 1975, this derivative offlurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals.[3]
It was patented in 1972 and came into medical use in 1984.[4]
Section 5.5 of the articleDoxefazepam in volume 66 of theWorld Health Organization's (WHO) andInternational Agency for Research on Cancer's (IARC)IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans, an article describing the carcinogenic/toxic effects of doxefazepam on humans and experimental animals, states that there is "inadequate evidence in humans for thecarcinogenicity of doxefazepam" and limited evidence in experimental for the carcinogenicity of doxefazepam," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."[5]
